The invention discloses a
hybrid capture kit for detecting tumor individually-medicated sixteen
gene hot spots. The
hybrid capture kit comprises a hybridization
reagent, a PCR amplification
reagent and an enrichment degree detection
reagent, wherein the hybridization reagent comprises an SEQ NO.1 to SEQ NO.396 probe mixture, a
molar ratio of every two probes is 1:1, and the use volume of the probemixture with the concentration being 10 nM each during detection is 1 [mu]l. The kit is
gene detection based on a second-generation sequencing technology, can detect three variation types (
mutation,
insertion deletion and fusion) one time, and uses a high sequencing depth to cover micro-scale
gene variation in order to accurately detect the
mutation condition of a patient on the premise of limited samples, and the
mutation frequency of 1% can be accurately detected.
Polygene and high-sensitivity
parallel detection improves the
detection rate of medicated gene variation, so the medication opportunity is not missed; and hot spots, rare and even unknown gene variation
cane be detected during one-time detection, and relevant
drug-resistant mutations (such as
KRAS and ALK
point mutation) are detected when
drug-sensitive variation is found, so the sensitivity and
drug resistance information of the medicated patient is accurately reflected.